decisionhealth Newsletters, Coder Pink Sheets - 2008 Issue 2 (February)
Specific informed consent needed for Avastin: OMIC
Subscribe or sign in to view the full article.
Article Overview
This article discusses ophthalmology risk-management guidance related to off-label use of Avastin for wet AMD. It focuses on informed consent, documentation, patient selection, diagnostic testing, and the role of FDA-approved alternatives. The content is relevant to ophthalmologists, coding and compliance staff, and medical record reviewers who need to understand the general documentation themes emphasized by OMIC.
Why This Topic Matters
Off-label drug use can raise documentation and consent concerns even when coverage exists. This article helps readers understand the broad compliance and recordkeeping issues that may affect ophthalmology practice, chart audit readiness, and patient communication.
What You Will Learn
- Why informed consent documentation is emphasized for off-label ophthalmic treatment
- What kinds of patient-selection and diagnostic documentation are highlighted
- How the article frames the relationship between approved alternatives and Avastin use
- What general recordkeeping elements OMIC says should be included in the chart
Who Should Read This
- Ophthalmologists
- Medical coders
- Compliance staff
- Practice managers
- Medical record auditors
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com